Mizuho Just Issued “Buy” Rating on Jazz Pharmaceuticals plc – Ordinary Shares (JAZZ)

Jazz Pharmaceuticals plc – Ordinary Shares (JAZZ) was Reiterated by Mizuho to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 152 from a previous price target of $127 . Mizuho advised their Clients and Investors in a research report released on Feb 21, 2017.

On the company’s financial health, Jazz Pharmaceuticals plc – Ordinary Shares reported $2.63 EPS for the quarter, missing the analyst consensus estimate by $ -0.18 based on the information available during the earnings call on Aug 9, 2016. Analyst had a consensus of $2.81. The company had revenue of $381.20 million for the quarter, compared to analysts expectations of $376.45 million. The company’s revenue was up 14.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.41 EPS.

Several company insiders have filed Insider transactions , on Feb 16, 2017, Michael Patrick Miller (SVP, US Commercial) sold 200 shares at $134.55 per share price. According to the SEC, on Jan 19, 2017, Russell J. Cox (EVP & COO) sold 4,000 shares at $127.50 per share price. On Dec 6, 2016, Patrick G Enright (director) sold 677 shares at $101.80 per share price, according to the Form-4 filing with the securities and exchange commission.

Jazz Pharmaceuticals plc – Ordinary Shares opened for trading at $136.37 and hit $137.56 on the upside on Friday, eventually ending the session at $137.19, with a gain of 0.57% or 0.78 points. The heightened volatility saw the trading volume jump to 4,60,285 shares. Company has a market cap of $8,217 M.

Jazz Pharmaceuticals plc - Ordinary Shares

Add Comment